← Back to Search

CAR T-cell Therapy

GDX012 for Acute Myeloid Leukemia

Phase 1 & 2
Recruiting
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing GDX012, a new cell therapy, in adult patients with Acute Myeloid Leukemia (AML). The goal is to see how safe and tolerable the treatment is and to find the best dose. GDX012 works by using specially modified cells to attack cancer cells.

Who is the study for?
Adults with a body weight of at least 40 kg who have relapsed or refractory Acute Myeloid Leukemia (AML) and are not eligible for stem cell transplantation can join. They should be in relatively good health otherwise, with an expected lifespan over 3 months and able to perform daily activities with little or no assistance.
What is being tested?
The trial is testing GDX012, a new cell therapy for AML. It aims to find out how safe the treatment is, how well patients tolerate it, and determine the best dose when combined with chemotherapy agents.
What are the potential side effects?
While specific side effects of GDX012 aren't listed here, common side effects from similar treatments include immune system reactions, fatigue, fever, digestive issues and potential risks associated with chemotherapy such as hair loss and increased infection risk.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Adverse Events (AEs)
Secondary study objectives
Duration of Response (DOR)
Event-free Survival (EFS)
Number of Participants With Disease Response
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 2a: GDX012Experimental Treatment2 Interventions
Participants will receive GDX012 (weight-based) IV infusion at pre-selected one or two dose levels from Phase 1, on Day 1 after lymphodepleting chemotherapy. Some participants may be eligible for a second dose.
Group II: Phase 1: Dose Escalation of GDX012Experimental Treatment2 Interventions
Participants will receive GDX012 weight-based dose as intravenous (IV) infusion on Day 1 of Phase 1 after lymphodepleting chemotherapy. Three dose levels of GDX012 will be tested in Phase 1. Some participants may be eligible for a second dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Chemotherapy Agents
2021
Completed Phase 2
~20

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for leukemia include chemotherapy, targeted therapy, and cell therapy. Chemotherapy uses drugs to kill rapidly dividing cells, including cancer cells, but can also affect healthy cells. Targeted therapy focuses on specific genetic mutations or proteins in cancer cells, minimizing damage to normal cells. Cell therapy, such as the investigational GDX012, involves modifying a patient's own immune cells to better recognize and attack cancer cells. This approach can provide a more precise and potent attack on leukemia cells while potentially reducing side effects. For leukemia patients, these treatments are crucial as they offer different strategies to combat the disease, improve survival rates, and enhance quality of life by targeting the cancer more effectively and sparing healthy tissues.
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,240 Previous Clinical Trials
4,149,418 Total Patients Enrolled
16 Trials studying Leukemia
3,317 Patients Enrolled for Leukemia
Study DirectorStudy DirectorTakeda
1,290 Previous Clinical Trials
502,459 Total Patients Enrolled
18 Trials studying Leukemia
4,421 Patients Enrolled for Leukemia

Media Library

GDX012 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05886491 — Phase 1 & 2
Leukemia Research Study Groups: Phase 1: Dose Escalation of GDX012, Phase 2a: GDX012
Leukemia Clinical Trial 2023: GDX012 Highlights & Side Effects. Trial Name: NCT05886491 — Phase 1 & 2
GDX012 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05886491 — Phase 1 & 2
~25 spots leftby Apr 2026